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Th e authors only included two studies with FL ( 4,5 )-in both of which the biomarker was able to discriminate between IBS and IBD. Yet, the analysis concludes that FL is not a useful biomarker. Th e authors use population rates of IBS and IBD (10% and 0.25%, respectively) in their naïve Bayes classifi er. Th is approach tacitly assumes clinicians weigh a 40-fold preference for IBS before considering other clinical information. Clinicians may or may not calibrate diagnostic preference based on population rates, but this modeling choice is probably one reason for the opposite conclusions of the meta-analysis and the constituent reports ( 6 ) . Th e authors also conclude a FL cutoff of 360 μ g/g indicates a patient is more probably aff ected by IBS than being healthy ( Figure 5, ( ref. 1 ) ), when studies show FL levels <7.25 μ g/g for patients with IBS and healthy controls ( 4, 5 ) .
In clinical practice most specialists use FC and FL markers interchangeably. Although more studies may be needed to confi rm that FC and FL are equivalent to diagnose and monitor IBD, the authors' conclusions that FL is clinically unhelpful is not currently justifi ed. ( 1 ) . Th e authors evaluated the utility of C-reactive protein (CRP), erythrocyte sedimentation rate, fecal calprotectin (FC), and fecal lactoferrin (FL) to separate patients with irritable bowel syndrome (IBS), from infl ammatory bowel disease (IBD) and healthy controls. Th eir results show that at a CRP level of ≤0.5 mg/dl or FC level of ≤40 μ g/g, there was a ≤1% probability of having IBD. However, erythrocyte sedimentation rate and FL had little clinical utility. Th ese results are unexpected, especially when compared with those of another meta-analysis ( 2 ) showing that CRP, FC, and FL are all useful biomarkers to diagnose and monitor IBD.
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Th e Menees meta-analysis ( 1 ) assumes that biomarkers are log-normally distributed. Th e mean and s.d. of each biomarker distribution were estimated only for those studies reporting medians and confi dence intervals, interquartile ranges, or range on the log scale. For FL, 12 studies reporting means and s.d. on the non-logged scale were excluded. Th is is surprising, because for given mean m and s.d. s from nonlogged data, the mean of the logged distribution is and s.d. is . Hence, the authors could have estimated the appropriate statistics in the Chinese materia medica, the fecal matter possesses more functions and indications than emetic and food poisoning. It is highly unlikely that the remarkable benefi ts of oral human fecal suspension or fermented fecal solution are purely due to eliminating poisons through the induction of vomiting or diarrhea. Especially, when this method was used at the time for bringing patients back from death. Because of limited space here we may address this question in another article.
Although traditional use of fecal matter in TCM is not synonymous with FMT in modern therapy, it is undoubtedly the truth that ancient Chinese doctors used human feces to treat severe diseases and that part of the benefi t may have been due to microbiota transplantation.We share Dr Brandt's hope that, in the future, "knowing we all stand on the shoulders of those who came before us, … the contributions made in every country the world over will be used by all for good purpose, and that mankind will benefi t" ( 2 ) .
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Letters to the Editor nature publishing group agogastroduodenoscopy (EGD) beginning at age 15 and repeated every 2 and 2-3 years, respectively. It appears that these recommendations are based on a report from Schreibman et al. ( 2 ) in 2005, where up to 60% Cowden syndrome patients had GI and colorectal polyps, predominantly hamartomas. Th e association between PHTS and GI cancer was not confi rmed at that time and therefore, Schreibman et al. ( 2 ) advised "a vigorous screening protocol" until further data becomes available.
In recent years, data regarding the GI manifestations in PHTS have been independently reported from several centers around the world. Collectively, it has been shown that up to 92% of individuals with PHTS who undergo colonoscopy have colorectal polyps, ranging from a few to innumerable polyps comprising a variety of histologies including hamartomas, adenomas, ganglioneuromas, serrated polyps, juvenile polyps, infl ammatory polyps, lymphoid aggregates, and normal colonic mucosa ( 3, 4 ) . Th e mean age when polyps were detected was 37 years ( 3, 4 ) . Individuals with PTEN mutations have also been found to be at an increased risk of colorectal cancer, which is estimated to be twofold to threefold above the general population, or a 9-18% lifetime risk ( 3, 4 ) . Among the groups from the United States, Israel, and France, the average age of colorectal cancer diagnosis was 46.7 years, while a European group found an average age at diagnosis of 57 years ( 3, 4 ) . Th e youngest reported patient with a PTEN mutation developing colorectal cancer is a 28-year-old reported by Kersseboom et al. ( 5 ) .
Upper GI polyps have been observed in 68-90% of patients with a mix of polyps with histologies similar to that observed in the colorectum ( 3,6,7 ). Upper GI tract cancers, including gastric (ages at diagnoses, 52 years and late 60s) and esophageal (ages, 33 and 41 years), are more rarely reported ( 6, 8, 9 ) .
On the basis of this contemporary body of literature, the available evidence would support a less aggressive recommendation for colorectal cancer (CRC) screening with colonoscopy beginning between ages 35 and 40 or 5 and 10 years earlier than the youngest age of CRC diagnosis in the family, whichever is earlier ( 3, 4, 6, 10 ) . Th e interval for repeat colonoscopy should be based on endoscopic fi ndings, with consideration of 
